syncytial virus

syncytial virus

a virus that induces the formation of syncytia, particularly in cell cultures.
References in periodicals archive ?
Respiratory syncytial virus (RSV) is the major cause of acute lower respiratory tract infections in young children, but very little is known about its epidemiology and circulating genotypes in Pakistan.
Regarding an earlier announcement on a cluster of patients infected with Respiratory Syncytial Virus in an infirmary ward, the spokesperson for Pok Oi Hospital (POH) gave the following update today (July 25):
M2 PHARMA-June 29, 2017-FDA Grants Clearance and CLIA Waiver to Quidel for Sofia 2 Instrument for Use with Respiratory Syncytial Virus Assay
MedImmune, AstraZeneca's biologics research and development unit, and France-based Sanofi Pasteur have agreed to collaborate to develop a monoclonal antibody treatment for respiratory syncytial virus, it was reported yesterday.
Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016', provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.
USPRwire, Tue Aug 18 2015] Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.
Objective: The respiratory syncytial virus (RSV) is the most significant viral pathogen causing bronchiolitis and pneumonia in infants, today.
Human respiratory syncytial virus (RSV) is the major viral cause of bronchiolitis and pneumonia in infants and also a major cause of severe respiratory illness in the elderly (1).
BASEL, Switzerland -- Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.
More information on the risks and severity of hypersensitivity reactions associated with the monoclonal antibody motavizumab is needed before it is approved for preventing serious lower respiratory tract infections with respiratory syncytial virus in high-risk infants, according to the majority of an FDA advisory panel.